Modular Analyzer Launched for High-Volume Laboratory Testing

The system also provides extensive modular flexibility so laboratories can configure tailored solutions to meet their individual needs.

The cobas 8000 series is a modular platform, which combines clinical chemistry and immunochemistry testing. The clinical chemistry menu includes tests for specific proteins, substrates, and enzymes. There are tests for therapeutic drug monitoring, drug and alcohol testing, and electrolytes. The immunochemistry module tests for biomarkers and antibodies for anemia, infectious diseases, cardiac diseases, bone markers, and thyroid function.

The cobas 8000 is the newest member of the modular platforms produced by Roche (Basel, Switzerland) and has received 510(k) clearance from the US Food and Drug Administration, (FDA; Silver Springs, MD, USA). The cobas 8000 modular analyzer series features intelligent sample routing with fast transportation and return lines, independent processing lines within each module, and a modular sample buffer in each module for true random-access sampling. The series also uses the same operator interface and the standardized reagent cassette concept used on other cobas analyzer platforms. Tests run on the new platform give physicians important clinical information in a wide range of medical areas, such as cardiac and infectious diseases, bone disorders and cancer.

Jack Phillips, president and CEO of Roche Diagnostics Corporation, said, "The cobas 8000 modular analyzer series delivers a new dimension in productivity, process innovation, and consolidation for high-volume laboratories. There are many innovative design elements that help reduce sample turnaround time, and the modular design gives laboratories the freedom to reconfigure their system on-site as they grow or their needs change."

Related Links:
Roche
FDA